Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates
Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of FDPS polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three...
Gespeichert in:
| Veröffentlicht in: | The pharmacogenomics journal 2012-06, Vol.12 (3), p.227-232 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 3 |
| container_start_page | 227 |
| container_title | The pharmacogenomics journal |
| container_volume | 12 |
| creator | Olmos, J M Zarrabeitia, M T Hernández, J L Sañudo, C González-Macías, J Riancho, J A |
| description | Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of
FDPS
polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of
FDPS
were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (
P
=0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (
P
=0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the
FDPS
gene influence the response to aminobisphosphonates. |
| doi_str_mv | 10.1038/tpj.2010.88 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1017981568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A292236718</galeid><sourcerecordid>A292236718</sourcerecordid><originalsourceid>FETCH-LOGICAL-c585t-24f899f1029356fc81cd6732925455cd40db2ee0b839d560c6e276724d6b42f13</originalsourceid><addsrcrecordid>eNqNksuLFDEQxhtR3HX15F0CXgTtMUl3Xsdl8AULXhS8hXS6MtNDd9ImaWWO_uemd9a3iOSQR_3qq6rwVdVDgjcEN_J5ng8bistNylvVOWlFUxPC8O3rM64pVx_OqnspHTAmnAh5tzqjBSBEyfPqyzZMU_DIjCOMg0WfTByMzwkFh_IekDPRQzqOqB_mfUjz3mRA6ejz3iRAO_CABu_GBbyF64QIaQ6-xIpASBnCHGLIRflzmMCjHFA3pJNU8EUs3a_uODMmeHCzX1TvX754t31dX7199WZ7eVVbJlmuaeukUo5gqhrGnZXE9lw0VFHWMmb7FvcdBcCdbFTPOLYcqOCCtj3vWupIc1E9OenOMXxcIGU9DcnCOBoPYUmaYCKUJIzL_0GZYJwqXNDHv6GHsERfBtGUt4SrwrB_UasWFYoL_oPamRF0-daQo7FraX1Z5qQNF2RtbvMXqqwepsEGD24o778kPD0l2BhSiuD0HIfJxGOprVcH6eIgvTpIy5V-dNPq0k3Qf2e_WaYAz05AKiG_g_jzLH_qfQXMoM6p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015279676</pqid></control><display><type>article</type><title>Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Olmos, J M ; Zarrabeitia, M T ; Hernández, J L ; Sañudo, C ; González-Macías, J ; Riancho, J A</creator><creatorcontrib>Olmos, J M ; Zarrabeitia, M T ; Hernández, J L ; Sañudo, C ; González-Macías, J ; Riancho, J A</creatorcontrib><description>Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of
FDPS
polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of
FDPS
were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (
P
=0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (
P
=0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the
FDPS
gene influence the response to aminobisphosphonates.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/tpj.2010.88</identifier><identifier>PMID: 21151198</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/2743/316/801 ; 692/700/565/1436/434 ; Absorptiometry, Photon ; Adult ; Aged ; Aged, 80 and over ; Alleles ; Analysis ; Analysis of Variance ; Biomedical and Life Sciences ; Biomedicine ; Bisphosphonates ; Bone Density - drug effects ; Bone Density - genetics ; Bone Density Conservation Agents - therapeutic use ; Bone mineral density ; Bone Resorption - drug therapy ; Bone Resorption - enzymology ; Bone Resorption - genetics ; Care and treatment ; Diphosphonates ; Diphosphonates - therapeutic use ; Drug therapy ; Estrogen receptors ; Female ; Gene Expression ; Gene Frequency ; Genetic aspects ; Geranyltranstransferase - genetics ; Geranyltranstransferase - metabolism ; Haplotypes ; Health aspects ; Human Genetics ; Humans ; Linear Models ; Linkage Disequilibrium ; Middle Aged ; Oncology ; original-article ; Osteoporosis ; Osteoporosis - diagnostic imaging ; Osteoporosis - drug therapy ; Osteoporosis - enzymology ; Osteoporosis - genetics ; Pharmacotherapy ; Phenotype ; Polymorphism, Single Nucleotide ; Post-menopause ; Postmenopausal women ; Psychopharmacology ; Raloxifene ; Risk Assessment ; Risk Factors ; Single nucleotide polymorphisms ; Single-nucleotide polymorphism ; Spain ; Time Factors ; Treatment Outcome</subject><ispartof>The pharmacogenomics journal, 2012-06, Vol.12 (3), p.227-232</ispartof><rights>Macmillan Publishers Limited 2012</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2012</rights><rights>Macmillan Publishers Limited 2012.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c585t-24f899f1029356fc81cd6732925455cd40db2ee0b839d560c6e276724d6b42f13</citedby><cites>FETCH-LOGICAL-c585t-24f899f1029356fc81cd6732925455cd40db2ee0b839d560c6e276724d6b42f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21151198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olmos, J M</creatorcontrib><creatorcontrib>Zarrabeitia, M T</creatorcontrib><creatorcontrib>Hernández, J L</creatorcontrib><creatorcontrib>Sañudo, C</creatorcontrib><creatorcontrib>González-Macías, J</creatorcontrib><creatorcontrib>Riancho, J A</creatorcontrib><title>Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of
FDPS
polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of
FDPS
were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (
P
=0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (
P
=0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the
FDPS
gene influence the response to aminobisphosphonates.</description><subject>692/699/2743/316/801</subject><subject>692/700/565/1436/434</subject><subject>Absorptiometry, Photon</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alleles</subject><subject>Analysis</subject><subject>Analysis of Variance</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bisphosphonates</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - genetics</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Bone mineral density</subject><subject>Bone Resorption - drug therapy</subject><subject>Bone Resorption - enzymology</subject><subject>Bone Resorption - genetics</subject><subject>Care and treatment</subject><subject>Diphosphonates</subject><subject>Diphosphonates - therapeutic use</subject><subject>Drug therapy</subject><subject>Estrogen receptors</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Gene Frequency</subject><subject>Genetic aspects</subject><subject>Geranyltranstransferase - genetics</subject><subject>Geranyltranstransferase - metabolism</subject><subject>Haplotypes</subject><subject>Health aspects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Linear Models</subject><subject>Linkage Disequilibrium</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>original-article</subject><subject>Osteoporosis</subject><subject>Osteoporosis - diagnostic imaging</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - enzymology</subject><subject>Osteoporosis - genetics</subject><subject>Pharmacotherapy</subject><subject>Phenotype</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Post-menopause</subject><subject>Postmenopausal women</subject><subject>Psychopharmacology</subject><subject>Raloxifene</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Single nucleotide polymorphisms</subject><subject>Single-nucleotide polymorphism</subject><subject>Spain</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNksuLFDEQxhtR3HX15F0CXgTtMUl3Xsdl8AULXhS8hXS6MtNDd9ImaWWO_uemd9a3iOSQR_3qq6rwVdVDgjcEN_J5ng8bistNylvVOWlFUxPC8O3rM64pVx_OqnspHTAmnAh5tzqjBSBEyfPqyzZMU_DIjCOMg0WfTByMzwkFh_IekDPRQzqOqB_mfUjz3mRA6ejz3iRAO_CABu_GBbyF64QIaQ6-xIpASBnCHGLIRflzmMCjHFA3pJNU8EUs3a_uODMmeHCzX1TvX754t31dX7199WZ7eVVbJlmuaeukUo5gqhrGnZXE9lw0VFHWMmb7FvcdBcCdbFTPOLYcqOCCtj3vWupIc1E9OenOMXxcIGU9DcnCOBoPYUmaYCKUJIzL_0GZYJwqXNDHv6GHsERfBtGUt4SrwrB_UasWFYoL_oPamRF0-daQo7FraX1Z5qQNF2RtbvMXqqwepsEGD24o778kPD0l2BhSiuD0HIfJxGOprVcH6eIgvTpIy5V-dNPq0k3Qf2e_WaYAz05AKiG_g_jzLH_qfQXMoM6p</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Olmos, J M</creator><creator>Zarrabeitia, M T</creator><creator>Hernández, J L</creator><creator>Sañudo, C</creator><creator>González-Macías, J</creator><creator>Riancho, J A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates</title><author>Olmos, J M ; Zarrabeitia, M T ; Hernández, J L ; Sañudo, C ; González-Macías, J ; Riancho, J A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c585t-24f899f1029356fc81cd6732925455cd40db2ee0b839d560c6e276724d6b42f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>692/699/2743/316/801</topic><topic>692/700/565/1436/434</topic><topic>Absorptiometry, Photon</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alleles</topic><topic>Analysis</topic><topic>Analysis of Variance</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bisphosphonates</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - genetics</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Bone mineral density</topic><topic>Bone Resorption - drug therapy</topic><topic>Bone Resorption - enzymology</topic><topic>Bone Resorption - genetics</topic><topic>Care and treatment</topic><topic>Diphosphonates</topic><topic>Diphosphonates - therapeutic use</topic><topic>Drug therapy</topic><topic>Estrogen receptors</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Gene Frequency</topic><topic>Genetic aspects</topic><topic>Geranyltranstransferase - genetics</topic><topic>Geranyltranstransferase - metabolism</topic><topic>Haplotypes</topic><topic>Health aspects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Linear Models</topic><topic>Linkage Disequilibrium</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>original-article</topic><topic>Osteoporosis</topic><topic>Osteoporosis - diagnostic imaging</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - enzymology</topic><topic>Osteoporosis - genetics</topic><topic>Pharmacotherapy</topic><topic>Phenotype</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Post-menopause</topic><topic>Postmenopausal women</topic><topic>Psychopharmacology</topic><topic>Raloxifene</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Single nucleotide polymorphisms</topic><topic>Single-nucleotide polymorphism</topic><topic>Spain</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olmos, J M</creatorcontrib><creatorcontrib>Zarrabeitia, M T</creatorcontrib><creatorcontrib>Hernández, J L</creatorcontrib><creatorcontrib>Sañudo, C</creatorcontrib><creatorcontrib>González-Macías, J</creatorcontrib><creatorcontrib>Riancho, J A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olmos, J M</au><au>Zarrabeitia, M T</au><au>Hernández, J L</au><au>Sañudo, C</au><au>González-Macías, J</au><au>Riancho, J A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>12</volume><issue>3</issue><spage>227</spage><epage>232</epage><pages>227-232</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>Farnesyl diphosphate synthase (FDPS) is necessary for osteoclast survival and activity and is considered as a major molecular target of aminobisphosphonates. Our objective was to analyze the influence of
FDPS
polymorphisms on bone mineral density (BMD) and the response to antiresortive drugs. Three single-nucleotide polymorphisms of
FDPS
were analyzed in 1186 postmenopausal women. There was only a marginally significant association of baseline hip BMD with rs11264359 alleles (
P
=0.043). However, among 191 women receiving antiresortive therapy, there was a very significant association between rs2297480 or rs11264359 alleles and the BMD changes after aminobisphosphonate therapy for an average period of 2.5 years (
P
=0.001). The genotype explained 7.2% of the variance in the BMD response. On the other hand, there was no association between the BMD changes after raloxifene therapy and any of the polymorphisms studied. These results suggest that common polymorphisms of the
FDPS
gene influence the response to aminobisphosphonates.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21151198</pmid><doi>10.1038/tpj.2010.88</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2012-06, Vol.12 (3), p.227-232 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1017981568 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | 692/699/2743/316/801 692/700/565/1436/434 Absorptiometry, Photon Adult Aged Aged, 80 and over Alleles Analysis Analysis of Variance Biomedical and Life Sciences Biomedicine Bisphosphonates Bone Density - drug effects Bone Density - genetics Bone Density Conservation Agents - therapeutic use Bone mineral density Bone Resorption - drug therapy Bone Resorption - enzymology Bone Resorption - genetics Care and treatment Diphosphonates Diphosphonates - therapeutic use Drug therapy Estrogen receptors Female Gene Expression Gene Frequency Genetic aspects Geranyltranstransferase - genetics Geranyltranstransferase - metabolism Haplotypes Health aspects Human Genetics Humans Linear Models Linkage Disequilibrium Middle Aged Oncology original-article Osteoporosis Osteoporosis - diagnostic imaging Osteoporosis - drug therapy Osteoporosis - enzymology Osteoporosis - genetics Pharmacotherapy Phenotype Polymorphism, Single Nucleotide Post-menopause Postmenopausal women Psychopharmacology Raloxifene Risk Assessment Risk Factors Single nucleotide polymorphisms Single-nucleotide polymorphism Spain Time Factors Treatment Outcome |
| title | Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T15%3A55%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Common%20allelic%20variants%20of%20the%20farnesyl%20diphosphate%20synthase%20gene%20influence%20the%20response%20of%20osteoporotic%20women%20to%20bisphosphonates&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Olmos,%20J%20M&rft.date=2012-06-01&rft.volume=12&rft.issue=3&rft.spage=227&rft.epage=232&rft.pages=227-232&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/tpj.2010.88&rft_dat=%3Cgale_proqu%3EA292236718%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015279676&rft_id=info:pmid/21151198&rft_galeid=A292236718&rfr_iscdi=true |